Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

Skin Cancer

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Eur J Cancer

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L

doi: 10.1016/j.ejca.2024.113976

Skin Cancer

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma

J Immunother

de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin O, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y

doi: 10.1097/CJI.0000000000000506

Skin Cancer

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Eur J Cancer

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS

doi: 10.1016/j.ejca.2024.113563

Skin Cancer

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Immunooncol Technol

König D, Kasenda B, Sandholzer M, Chirindel A, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer D, Kettelhack C, Passweg J, Baur K, Holbro A, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Matter MS, Rodrigues Mantuano N, Binder M, Zippelius A, Läubli H

doi: 10.1016/j.iotech.2024.100728

Skin Cancer

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

J Clin Oncol

Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS

doi: 10.1200/JCO.24.00400

Skin Cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

Int J Cancer

Bloem M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, de Groot JB, Haanen JB, Hospers GAP, Kapiteijn EW, de Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM

doi: 10.1002/ijc.35060

ESMO 2024

Lung, Respiratory and Thoracic Cancer

TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases

ESMO 2024

Skin Cancer

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

Further Publications

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Eur Radiol

Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, Maintz D, Kreuzberg N, Wolf J, Bröckelmann PJ, Lennartz S

doi: 10.1007/s00330-024-11060-4

Related content

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases

CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients